Amgen announces phase 3 CANDOR study meets primary endpoint
Amgen announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) compared to KYPROLIS and dexamethasone alone met its primary endpoint of progression-free survival. September 13, 2019